|
rs9282858
|
|
|
0.060 |
GeneticVariation |
BEFREE |
<b>Results:</b><i>SRD5A2</i> rs9282858 (A49T) polymorphism showed a significant correlation with increased B</span>PH susceptibility under allele T vs.allele A genetic model (OR = 2.51, 95% CI = 1.29-4.88) in total analysis, and stratification analysis by ethnicity also revealed a similar association in Caucasian group under the same contrast.
|
28955247 |
2017 |
|
rs523349
|
|
|
0.080 |
GeneticVariation |
BEFREE |
<i>SRD5A2</i> rs523349 (V89L) polymorphism showed no significant role in BPH occurrence in total analysis, but its reducing and increasing effects on the disease risk were reflected in Caucasian and other-ethnicity subgroups, respectively, after stratification analysis by ethnicity.
|
28955247 |
2017 |
|
rs4792311
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Ser217Leu and Ala541Thr variants carried no significantly elevated risk for HPC or PRCA, although the latter variant was associated with benign prostatic hyperplasia.
|
11507049 |
2001 |
|
rs3803185
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Cys148Arg genotypes and expression of the ARLTS1 were explored in a large set of familial and unselected PCa cases, clinical tumor samples, xenografts, prostate cancer cell lines and benign prostatic hyperplasia (BPH) samples.
|
22028916 |
2011 |
|
rs16902947
|
|
|
0.010 |
GeneticVariation |
BEFREE |
rs16902947, rs16902947 and rs4646437 single nucleotide polymorphisms are significantly associated with the clinical characteristics of benign prostatic hyperplasia and the efficacy of benign prostatic hyperplasia treatment.
|
28787260 |
2017 |
|
rs17144046
|
|
G |
0.700 |
GeneticVariation |
GWASCAT |
A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).
|
28656603 |
2017 |
|
rs680055
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After considering the potential for false positive associations, the only remaining significant associations involved CYP3A43 P340A genotypes and history of BPH on both Gleason grade (interaction p-value = 0.026) and tumor stage (interaction p-value = 0.017).
|
18566991 |
2008 |
|
rs2745557
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Also, the coexistence of COX-2 (rs2745557) and obesity, smoking, or diabetes may lead to the development of PCa or BPH.
|
26920155 |
2016 |
|
rs523349
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Although V89L was nonsignificantly associated with BPH in overall population, BPH risk increased significantly with the number of L alleles in Hispanics (P for trend=0.03).
|
16018939 |
2005 |
|
rs78105154
|
|
|
0.010 |
GeneticVariation |
BEFREE |
An epidemiological study was done in sporadic PCa (n=98) and BPH (n=143) using 1 novel (Ser627Leu) and 2 previously described polymorphisms of the HPC2/ELAC2 gene.
|
12949798 |
2003 |
|
rs103294
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Association between rs103294, BPH risk and clinicopathological traits were tested with adjustment for age. rs103294 was significantly associated with BPH risk with a p-value of 0.0067.
|
23615473 |
2013 |
|
rs523349
|
|
|
0.080 |
GeneticVariation |
BEFREE |
CYP19 1531 C>T, SRD5A2 gene V89L, CYP17 gene -34 T/C, PSA-158 (G/A) regions were evaluated for the association between polymorphisms and benign prostatic hyperplasia and prostate cancer in study population.
|
26214411 |
2015 |
|
rs523349
|
|
|
0.080 |
GeneticVariation |
BEFREE |
For the V89L polymorphism there were no significant differences in genotype frequencies in patients with prostate cancer and controls (p = 0.071) or in patients with BPH and male controls (p = 0.219).
|
12771801 |
2003 |
|
rs1902023
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, we observed that the D85Y polymorphism increases the risk of BPH when analyzed in combination with the copy number variation of UGT2B17 gene (OR=0.135; 95% CI, 0.036-0.512; p=0.003).
|
28882566 |
2017 |
|
rs72551387
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, we observed that the D85Y polymorphism increases the risk of BPH when analyzed in combination with the copy number variation of UGT2B17 gene (OR=0.135; 95% CI, 0.036-0.512; p=0.003).
|
28882566 |
2017 |
|
rs10054105
|
|
T |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.
|
30410027 |
2018 |
|
rs11084596
|
|
T |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.
|
30410027 |
2018 |
|
rs11199879
|
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.
|
30410027 |
2018 |
|
rs11651052
|
|
G |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.
|
30410027 |
2018 |
|
rs148678804
|
|
A |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.
|
30410027 |
2018 |
|
rs1638703
|
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.
|
30410027 |
2018 |
|
rs200383755
|
|
G |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.
|
30410027 |
2018 |
|
rs200476
|
|
A |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.
|
30410027 |
2018 |
|
rs2555019
|
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.
|
30410027 |
2018 |
|
rs2556378
|
|
T |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.
|
30410027 |
2018 |